Assessing long-term maintenance of efficacy with tralokinumab monotherapy in patients with moderate-to-severe atopic dermatitis: Combined results from two phase 3, randomized, double-blind, placebo-controlled trials (ECZTRA 1 and 2)

被引：0

作者：

Blauvelt, Andrew ^{[1
]}

Wollenberg, Andreas ^{[2
]}

Pink, Andrew ^{[3
]}

Peris, Ketty ^{[4
,5
]}

Gemelli, A.

Armstrong, April ^{[6
]}

Spelman, Lynda ^{[7
]}

Saeki, Hidehisa ^{[8
]}

Lynde, Charles ^{[9
,10
]}

Herranz, Pedro ^{[11
]}

Barbarot, Sebastien ^{[12
]}

Simpson, Eric ^{[13
]}

机构：

[1] Oregon Med Res Ctr, Portland, OR USA

[2] Ludwig Maximilian Univ Munich, Dept Dermatol & Allergol, Munich, Germany

[3] Guys & St Thomas Hosp, St Johns Inst Dermatol, London, England

[4] Catholic Univ, Dermatol, Milan, Italy

[5] Fdn Policlin Univ A Gemelli, IRCCS, Rome, Italy

[6] Univ Southern Calif, Keck Sch Med, Dept Dermatol, Los Angeles, CA 90007 USA

[7] Verac Clin Res, Woolloongabba, Qld, Australia

[8] Nippon Med Sch, Dept Dermatol, Tokyo, Japan

[9] Univ Toronto, Prob Med Res, Lynde Dermatol, Toronto, ON, Canada

[10] Univ Toronto, Dept Med, Toronto, ON, Canada

[11] Hosp Univ La Paz, Dept Dermatol, Madrid, Spain

[12] CHU Nantes, Nantes, France

[13] Oregon Hlth & Sci Univ, Dept Dermatol, Portland, OR 97201 USA

来源：

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY | 2021年 / 85卷 / 03期

关键词：

D O I：

暂无

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

28171

引用

页码：AB177 / AB177

页数：1

共 50 条

[31] Specifically targeting interleukin-13 with tralokinumab improved sleep in two phase III, randomized, double-blind, placebo-controlled trials in patients with atopic dermatitis
Silverberg, J. I.
Barbarot, S.
Gooderham, M.
Simon, J. C.
Simpson, E.
Kurbasic, A.
Olsen, C. K.
Cork, M. J.
BRITISH JOURNAL OF DERMATOLOGY, 2021, 184 (03) : E64 - E65
[32] Dupilumab in moderate-to-severe atopic dermatitis: results from two randomized phase 3 trials (SOLO 1 & 2)
Simpson, E. L.
Bieber, T.
Guttman-Yassky, E.
Beck, L. A.
Blauvelt, A.
Cork, M. J.
Silverberg, J. I.
Deleuran, M.
Kataoka, Y.
Lacour, J. -P.
Kingo, K.
Worm, M.
Poulin, Y.
Wollenberg, A.
Soo, Y.
Graham, N. M. H.
Pirozzi, G.
Akinlade, B.
Staudinger, H.
Mastey, V.
Eckert, L.
Gadkari, A.
Ardeleanu, M.
JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2017, 15 : 79 - 79
[33] EFFICACY AND SAFETY OF DUPILUMAB IN THE TREATMENT OF MODERATE-TO-SEVERE ATOPIC DERMATITIS IN CHINESE ADULTS: A MULTICENTER, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 TRIAL
Zhao, Yan
Wu, Liming
Lu, Qianjin
Gao, Xinghua
Zhu, Xiaohong
Yao, Xu
Li, Linfeng
Li, Wei
Ding, Yangfeng
Song, Zhiqiang
Liu, Lingling
Dang, Ningning
Zhang, Chunlei
Liu, Xiaoming
Gu, Jun
Wang, Jinyan
Geng, Songhai
Liu, Qunazhong
Guo, Yifeng
Lv, Dong
Ren, Gong
Yang, Xiumin
Deng, Danqi
Li, Shanshan
Han, Xiuping
Biao, Shuzhen
Zheng, Min
Dong, Li
Su, Huijuan
Bai, Lili
O'Malley, John T.
Luo, Junxiang
Zhang, Jianzhong
ACTA DERMATO-VENEREOLOGICA, 2021, 101 : 58 - 58
[34] Efficacy of Dupilumab in Different Racial Subgroups of Adults With Moderate-to-Severe Atopic Dermatitis in Three Randomized, Placebo-Controlled Phase 3 Trials
Alexis, Andrew F.
Rendon, Marta
Silverberg, Jonathan I.
Pariser, David M.
Lockshin, Benjamin
Griffiths, Christopher E. M.
Weisman, Jamie
Wollenberg, Andreas
Chen, Zhen
Davis, John D.
Li, Meng
Eckert, Laurent
Gadkari, Abhijit
Shumel, Brad
Rossi, Ana B.
Graham, Neil M. H.
Ardeleanu, Marius
JOURNAL OF DRUGS IN DERMATOLOGY, 2019, 18 (08) : 804 - 813
[35] The efficacy of whey associated with dodder seed extract on moderate-to-severe atopic dermatitis in adults: A randomized, double-blind, placebo-controlled clinical trial
Mehrbani, Mehrzad
Choopani, Rasool
Fekri, Alireza
Mehrabani, Mitra
Mosaddegh, Mahmoud
Mehrabani, Mehrnaz
JOURNAL OF ETHNOPHARMACOLOGY, 2015, 172 : 325 - 332
[36] Efficacy and safety of memantine in patients with moderate-to-severe Alzheimer's disease: results of a pooled analysis of two randomized, double-blind, placebo-controlled trials in Japan
Nakamura, Yu
Kitamura, Shin
Homma, Akira
Shiosakai, Kazuhito
Matsui, Daiju
EXPERT OPINION ON PHARMACOTHERAPY, 2014, 15 (07) : 913 - 925
[37] Long-term efficacy and safety of itolizumab in patients with moderate-to-severe chronic plaque psoriasis: A double-blind, randomized-withdrawal, placebo-controlled study
Dogra, Sunil
Krupashankar
Budamakuntla, Leelavathy
Srinivas, C. R.
Khopkar, Uday
Gupta, Sandesh
Shetty, Narendra
Pratap, Dasiga Venkata Subrahmanya
Gopal, M. G.
Rao, T. Narayana
Garg, Vijay
Sumathy, T. K.
Saraswat, Abir
Bhat, Ramesh
Kura, Mahendra
Pandey, Neeraj
Shah, Radha
Krishna, Kotla Sai
Padmaja, Dalavai
Manmohan, G.
Ramakrishnan, M. S.
Barve, Abhijit
Montero, Enrique
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2015, 73 (02) : 331 - 333
[38] The effect of dupilumab on vaccine antibody responses in adults with moderate-to-severe atopic dermatitis: a randomized, double-blind, placebo-controlled trial
Blauvelt, A.
Simpson, E.
Wu, R.
Akinlade, B.
Graham, N.
Pirozzi, G.
Evans, R.
ALLERGY, 2016, 71 : 95 - 95
[39] Spesolimab, an anti-interleukin-36 receptor antibody, in patients with moderate-to-severe atopic dermatitis: Results from a multicentre, randomized, double-blind, placebo-controlled, phase IIa study
Bissonnette, Robert
Abramovits, William
Proulx, Etienne Saint-Cyr
Lee, Patricia
Guttman-Yassky, Emma
Zovko, Elizabeta
Sigmund, Ralf
Willcox, Joanne
Bieber, Thomas
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2023, 37 (03) : 549 - 557
[40] Efficacy and Safety of Epratuzumab in Patients with Moderate-to-Severe Systemic Lupus Erythematosus: Results from Two Phase 3 Randomized, Placebo-Controlled Trials
Clowse, Megan E. B.
Wallace, Daniel J.
Furie, Richard
Petri, Michelle
Pike, Marilyn
Leszczynski, Piotr
Neuwelt, C. Michael
Hobbs, Kathryn
Keiserman, Mauro
Duca, Liliana
Kalunian, Kenneth
Bongardt, Sabine
Stach, Christian
Beaudot, Carolyn
Kilgallen, Brian
Galateanu, Catrinel
Gordon, Caroline
ARTHRITIS & RHEUMATOLOGY, 2015, 67

← 1 2 3 4 5 →